{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:56:59Z","timestamp":1760237819072,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B2003590"],"award-info":[{"award-number":["2018R1A2B2003590"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Double-hit lymphoma (DHL) and double-expressor lymphoma (DEL) are aggressive forms of lymphoma that require better treatments to improve patient outcomes. CKD-581 is a new histone deacetylase (HDAC) inhibitor that exhibited a better safety profile in clinical trials compared to other HDAC inhibitors. Here, we demonstrate that CKD-581 inhibited the class I\u2013II HDAC family via histone H3 and tubulin acetylation. CKD-581 treatment also up-regulated the phosphorylation of histone H2AX (\u03b3H2AX, DNA double-strand break marker), and reduced levels of MYC and anti-apoptotic proteins such as BCL-2, BCL-6, BCL-XL, and MCL-1 in DH\/DE-diffuse large B cell lymphoma (DLBCL) cell lines. Ultimately, CKD-581 also induced apoptosis via poly(ADP ribose) polymerase 1 (PARP1) cleavage. In a DLBCL SCID mouse xenograft model, CKD-581 exhibited anti-cancer effects comparable with those of rituximab (CD20 mAb). Our findings suggest that CKD-581 could be a good candidate for the treatment of DLBCL.<\/jats:p>","DOI":"10.3390\/ijms21124377","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T10:43:58Z","timestamp":1592563438000},"page":"4377","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"21","author":[{"given":"Soo Jin","family":"Kim","sequence":"first","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"},{"name":"CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation, Gyeonggi-do 16995, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U Ji","family":"Kim","sequence":"additional","affiliation":[{"name":"CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation, Gyeonggi-do 16995, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Yong","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University, Seoul 08826, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong June","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5858\/2008-132-118-DLBL","article-title":"Diffuse large B-cell lymphoma","volume":"132","author":"Hunt","year":"2008","journal-title":"Arch. Pathol. Lab Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","article-title":"Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: Analysis of data from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte\/lymphoma study association phase III trial LNH 03-2B","volume":"32","author":"Molina","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11912-009-0052-0","article-title":"Second-line treatment paradigms for diffuse large B-cell lymphomas","volume":"11","author":"Thieblemont","year":"2009","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches","volume":"120","author":"Petrich","year":"2014","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","article-title":"Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1158\/1535-7163.MCT-17-0089","article-title":"Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas","volume":"16","author":"Islam","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/14737140.2015.1009042","article-title":"Emerging drugs for diffuse large B-cell lymphoma","volume":"15","author":"Mondello","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/10428194.2019.1691194","article-title":"Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16495","DOI":"10.1038\/s41598-019-52714-4","article-title":"Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells","volume":"9","author":"Cortiguera","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10637-018-0582-0","article-title":"Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy","volume":"36","author":"Cho","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_17","first-page":"166","article-title":"Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.tranon.2018.07.007","article-title":"Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression","volume":"11","author":"Deng","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_19","first-page":"171","article-title":"PARP cleavage as a means of assessing apoptosis","volume":"88","author":"Mullen","year":"2004","journal-title":"Methods Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 Family in B Cell Lymphoma","volume":"8","author":"Adams","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/blood-2011-07-367672","article-title":"Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice","volume":"118","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","author":"Kelly","year":"2014","journal-title":"Genes Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2003-10-3399","article-title":"Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies","volume":"103","author":"Linden","year":"2004","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1182\/blood.V97.12.3902","article-title":"MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes","volume":"97","author":"Zhou","year":"2001","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2007-11-124487","article-title":"Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis","volume":"112","author":"Stolz","year":"2008","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Thompson, R.C., Vardinogiannis, I., and Gilmore, T.D. (2013). The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062822"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Oncol. Targets Ther."},{"key":"ref_29","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","article-title":"Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer","volume":"26","author":"Vansteenkiste","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002800050922","article-title":"Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats","volume":"43","author":"Egorin","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","first-page":"2330","article-title":"Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia","volume":"7","author":"Gore","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_38","unstructured":"Wu, M., Sirota, M., Butte, A.J., and Chen, B. (2015). Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov. Pac. Symp. Biocomput., 68\u201379."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Imai, Y., Hirano, M., Kobayashi, M., Futami, M., and Tojo, A. (2019). HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers, 11.","DOI":"10.3390\/cancers11040475"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-14-3068","article-title":"Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma","volume":"21","author":"Amengual","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-16-2022","article-title":"Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib","volume":"23","author":"Amengual","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4377\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:40:57Z","timestamp":1760175657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21124377"],"URL":"https:\/\/doi.org\/10.3390\/ijms21124377","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}